June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
Genetic testing yield among patients with suspected primary heritable optic atrophy
Author Affiliations & Notes
  • Maureen C Farrell
    Ophthalmic Genetics and Visual Function Branch, National Eye Institute, Bethesda, Maryland, United States
  • Celeste D’Amanda
    Ophthalmic Genetics and Visual Function Branch, National Eye Institute, Bethesda, Maryland, United States
  • Ehsan Ullah
    Ophthalmic Genetics and Visual Function Branch, National Eye Institute, Bethesda, Maryland, United States
    Ophthalmic Genomics Laboratory, National Eye Institute, Bethesda, Maryland, United States
  • Bin Guan
    Ophthalmic Genetics and Visual Function Branch, National Eye Institute, Bethesda, Maryland, United States
    Ophthalmic Genomics Laboratory, National Eye Institute, Bethesda, Maryland, United States
  • Delphine Blain
    Ophthalmic Genetics and Visual Function Branch, National Eye Institute, Bethesda, Maryland, United States
    Ophthalmic Clinical Genetics Section, National Eye Institute, Bethesda, Maryland, United States
  • Amy Turriff
    Ophthalmic Clinical Genetics Section, National Eye Institute, Bethesda, Maryland, United States
    Ophthalmic Genetics and Visual Function Branch, National Eye Institute, Bethesda, Maryland, United States
  • Wai T Wong
    Section on Neuron-Glia Interactions, National Eye Institute, Bethesda, Maryland, United States
  • Catherine A Cukras
    Unit on Clinical Investigation of Retinal Disease, National Eye Institute, Bethesda, Maryland, United States
  • Steven F Stasheff
    Ophthalmic Genetics and Visual Function Branch, National Eye Institute, Bethesda, Maryland, United States
    Neuro-Ophthalmology, Children's National Hospital, Washington, District of Columbia, United States
  • Edmond J FitzGibbon
    Acuity Section, National Eye Institute, Bethesda, Maryland, United States
  • Wadih M Zein
    Ophthalmic Clinical Genetics Section, National Eye Institute, Bethesda, Maryland, United States
  • Brian P Brooks
    Ophthalmic Genetics and Visual Function Branch, National Eye Institute, Bethesda, Maryland, United States
    Pediatric, Developmental & Genetic Ophthalmology Section, National Eye Institute, Bethesda, Maryland, United States
  • Laryssa A Huryn
    Ophthalmic Clinical Genetics Section, National Eye Institute, Bethesda, Maryland, United States
  • Robert B Hufnagel
    Medical Genetics and Ophthalmic Genomics Unit, National Eye Institute, Bethesda, Maryland, United States
    Ophthalmic Genomics Laboratory, National Eye Institute, Bethesda, Maryland, United States
  • Footnotes
    Commercial Relationships   Maureen Farrell, None; Celeste D’Amanda, None; Ehsan Ullah, None; Bin Guan, None; Delphine Blain, None; Amy Turriff, None; Wai T Wong, None; Catherine Cukras, None; Steven Stasheff, None; Edmond FitzGibbon, None; Wadih Zein, None; Brian Brooks, None; Laryssa Huryn, None; Robert Hufnagel, None
  • Footnotes
    Support  NEI intramural funds
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 1553. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Maureen C Farrell, Celeste D’Amanda, Ehsan Ullah, Bin Guan, Delphine Blain, Amy Turriff, Wai T Wong, Catherine A Cukras, Steven F Stasheff, Edmond J FitzGibbon, Wadih M Zein, Brian P Brooks, Laryssa A Huryn, Robert B Hufnagel; Genetic testing yield among patients with suspected primary heritable optic atrophy. Invest. Ophthalmol. Vis. Sci. 2021;62(8):1553.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The clinical and genetic heterogeneity of suspected primary heritable optic atrophy (phOA) poses genetic diagnostic challenges. Patients with suspected phOA were retrospectively analyzed to determine genetic testing yield and clinical correlates.

Methods : Medical records of patients with genetic testing for suspected phOA were reviewed. Sex, age at vision symptom onset (VSO) and OA diagnosis (OAD), clinical diagnosis subgroup, presence of syndromic features, and positive family history were analyzed. Clinical diagnosis subgroups included 1) Dominant Optic Atrophy (DOA) (OPA1 or OPA3), 2) Leber Hereditary Optic Neuropathy (LHON), 3) unspecified isolated OA, and 4) syndromic OA. Probands underwent Sanger Sequencing, Next Generation Sequencing, and/or whole exome sequencing. Molecular confirmation indicated presence of pathogenic variants

Results : Fifty unique probands with suspected phOA were identified (32 male, 18 female). Mean ages were 22±20 years (standard deviation) for VSO and 26±21 years for OAD. Testing confirmed molecular causes in 30% of cases (15/50), including 11/32 males and 4/18 females (not significant; Fisher’s exact test). Molecular testing result stratified by clinical diagnosis subgroup confirmed disease-causing genotypes in 6/23 with suspected DOA, 4/6 with suspected LHON, 2/8 with unspecified isolated OA, and 3/13 with suspected syndromic OA. Age at VSO and OAD between molecularly confirmed vs. unconfirmed cases were not statistically different. Isolated OA was reported in 42 probands (84%) and suspected syndromic OA in 8 probands (16%); genetic testing yield was not different between these groups (31% vs. 25% respectively; Fisher’s test). Genetic testing yield was 60% for probands with positive family history (9/15) and 19% for singletons (6/32) (p=0.0077; Fisher’s test).

Conclusions : Consistent with prior studies, family history was positively associated with testing yield, but was not significantly affected by sex, clinical diagnosis subgroup, or presence of syndromic features. A large prospective phOA cohort is needed to identify and refine clinical associations and drive gene discovery required to improve genetic diagnostic yield among unconfirmed patients.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×